American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Autor: Sheila E. Taube, Daniel F. Hayes, Herbert A. Fritsche, Mark R. Somerfield, Robert C. Bast, Lyndsay Harris, Robert G. Mennel, Larry Norton, Peter M. Ravdin
Rok vydání: 2007
Předmět:
Oncology
Proteomics
Cancer Research
medicine.medical_specialty
Receptor
ErbB-2
MEDLINE
Breast Neoplasms
Health outcomes
Cathepsin D
Quality of life (healthcare)
Breast cancer
MammaPrint
Bone Marrow
Internal medicine
Cyclin E
Plasminogen Activator Inhibitor 1
Biomarkers
Tumor
Humans
Medicine
Antigens
Tumor-Associated
Carbohydrate
Cell Proliferation
Tumor marker
Clinical Oncology
Cochrane collaboration
medicine.diagnostic_test
Oncology (nursing)
business.industry
Oncotype DX Breast Cancer Assay
Health Policy
Gene Expression Profiling
Mucin-1
Current Clinical Issues
Neoplastic Cells
Circulating
medicine.disease
Urokinase-Type Plasminogen Activator
Carcinoembryonic Antigen
Systematic review
Receptors
Estrogen
Drug Resistance
Neoplasm
Family medicine
Practice Guidelines as Topic
Immunology
Female
Tumor Suppressor Protein p53
Receptors
Progesterone
business
Oncotype DX
Zdroj: Journal of Clinical Oncology. 25:5287-5312
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2007.14.2364
Popis: PurposeTo update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer.MethodsFor the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee's literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations.Recommendations and ConclusionsThirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells.
Databáze: OpenAIRE
Externí odkaz: